Amgen Q4 Earnings Preview: Street expects revenue to rise more than 8%
Biopharmaceutical company Amgen (NASDAQ:AMGN) is set to announce its fourth quarter earnings results on Tuesday, February 4th, after the closing bell. Wall Street expects the company to report a 7.9% increase in earnings per share to $5.
Amgen Inc (AMGN) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic Expansions
Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, despite facing market challenges.
Amgen Surpasses Q4 Earnings Forecasts
Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.
Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating
Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read why AMGN stock is a Buy.
Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead
Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.
Amgen Reports More Than $2B in Oncology Revenues in Q4
Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.
Amgen Inc. Q4 Profit Decreases, But Beats Estimates
Amgen Inc. (AMGN) reported a profit for fourth quarter that decreased from the same period last year but beat the Street estimates.
Amgen: Q4 Earnings Snapshot
The average estimate of 13 analysts surveyed by Zacks Investment Research was for earnings of $5.03 per share. The world's largest biotech drugmaker posted revenue of $9.09 billion in the period, also beating Street forecasts.
Compared to Estimates, Amgen (AMGN) Q4 Earnings: A Look at Key Metrics
Amgen (AMGN) reported $9.09 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 10.9%. EPS of $5.31 for the same period compares to $4.71 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $8.
FiercePharma14h
With recent launches and more to come, Amgen's biosimilar business is trending up
After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...
StockStory.org on MSN11h
Why Amgen (AMGN) Stock Is Trading Up Today
What Happened? Shares of biotech company Amgen (NASDAQ:AMGN) jumped 5.3% in the morning session after the company reported ...
Amgen profits rise, next MariTide studies start by mid-year
Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...
Amgen price target raised to $328 from $322 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Amgen (AMGN) to $328 from $322 and keeps an Equal Weight rating on the ...
Amgen 4Q Sales Up 11% as Ten Products Post Double-Digit Gains
Product sales rose 11%, led by 14% volume growth. Products including Repatha, Blincyto and Tezspire all posted at least double digit sales growth, the company said. For the current year, Amgen expects ...
Amgen targets $34.3B-$35.7B in 2025 revenues with strong growth in key therapeutic areas
Q4 2024 Management View Amgen highlighted its robust performance in 2024, achieving 14 products annualizing over $1 billion in sales. CEO Robert Bradway emphasized the company's resilience in ...
AMGN Earnings: Amgen Slips on Soft EPS Guidance
Shares of Amgen (AMGN) fell in after-hours trading after the biotechnology company reported earnings for its fourth quarter ...
Amgen's SWOT analysis: stock outlook amid obesity drug race
Amgen Inc (NASDAQ:AMGN)., a leading biopharmaceutical company with a market capitalization of $155 billion, is at a pivotal juncture as it navigates the competitive landscape of innovative ...